An Assay Suitable for High Throughput Screening of Anti-Influenza Drugs

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Mao, Lili ^a,c   Wang, Jun ^b   DeGrado, William F ^b   Inouye, Masayori ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ION CHANNEL; ION CHANNEL M2; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG SCREENING; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; INFLUENZA VIRUS A; NONHUMAN; SINGLE PROTEIN PRODUCTION SYSTEM;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MUTATION; RECOMBINANT PROTEINS; VIRAL MATRIX PROTEINS;

INFLUENZA A VIRUS;

EID: 84872243108     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054070     Document Type: Article

References (17)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
2. CDC (2009) Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009- April 10, 2010. Available: http://wwwcdcgov/h1n1flu/estimates_2009_h1n1htm.
3. Monto AS, (2006) Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 12: 55-60.
4. Moscona A, (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373.
5. De Clercq E, (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5: 1015-1025.
6. Suzuki M, Zhang J, Liu M, Woychik NA, Inouye M, (2005) Single protein production in living cells facilitated by an mRNA interferase. Mol Cell 18: 253-261.
7. Suzuki M, Mao L, Inouye M, (2007) Single protein production (SPP) system in Escherichia coli. Nat Protoc 2: 1802-1810.
8. Mould JA, Drury JE, Frings SM, Kaupp UB, Pekosz A, et al. (2000) Permeation and activation of the M2 ion channel of influenza A virus. J Biol Chem 275: 31038-31050.
9. Ohshima M, Inoue K, Hayashi H, Tsuji D, Mizugaki M, et al. (2010) Generation of AcGFP fusion with single-chain Fv selected from a phage display library constructed from mice hyperimmunized against 5-methyl 2′-deoxycytidine. Protein Eng Des Sel 23: 881-888.
10. Balannik V, Carnevale V, Fiorin G, Levine BG, Lamb RA, et al. (2010) Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel. Biochemistry 49: 696-708.
11. Wang J, Ma C, Wu Y, Lamb RA, Pinto LH, et al. (2011) Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. J Am Chem Soc 133: 13844-13847.
12. Balannik V, Wang J, Ohigashi Y, Jing XH, Magavern E, et al. (2009) Design and Pharmacological Characterization of Inhibitors of Amantadine-Resistant Mutants of the M2 Ion Channel of Influenza A Virus. Biochemistry 48: 11872-11882.
13. Wang J, Ma CL, Fiorin G, Carnevale V, Wang T, et al. (2011) Molecular Dynamics Simulation Directed Rational Design of Inhibitors Targeting Drug-Resistant Mutants of Influenza A Virus M2. Journal of the American Chemical Society 133: 12834-12841.
14. Astrahan P, Flitman-Tene R, Bennett ER, Krugliak M, Gilon C, et al. (2011) Quantitative analysis of influenza M2 channel blockers. Biochim Biophys Acta 1808: 394-398.
15. Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, et al. (2008) Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A 105: 10967-10972.
16. Griffin SD, (2009) Plugging the holes in hepatitis C virus antiviral therapy. Proc Natl Acad Sci U S A 106: 12567-12568.
17. Hout DR, Mulcahy ER, Pacyniak E, Gomez LM, Gomez ML, et al. (2004) Vpu: a multifunctional protein that enhances the pathogenesis of human immunodeficiency virus type 1. Curr HIV Res 2: 255-270.